Myriad Genetics, a leader in molecular diagnostics, presented compelling data at the 2026 ASCO Annual Meeting regarding its Precise MRD (molecular residual disease) test. The test's efficacy was highlighted through six poster presentations, particularly the interim results from the MONSTAR-SCREEN-3 study, which involved over 1,100 patients undergoing treatment for various solid tumors. Dr. Takayuki Yoshino reported that the test achieved a 97% baseline detection rate, with 16% of samples detected at ultrasensitive levels. Notably, patients who tested positive for circulating tumor DNA (ctDNA) one month after surgery faced a significantly higher risk of recurrence, underscoring the test's potential to inform treatment decisions. Myriad's Chief Scientific Officer, Dale Muzzey, emphasized the importance of sensitive detection in improving clinical outcomes. The conference also featured discussions on the test's application in multiple cancer types, including ovarian and gastric cancers. Myriad Genetics aims to set a new benchmark in cancer care through this innovative approach, which could revolutionize how oncologists monitor and respond to disease progression.